Can one injection replace two? DifGen’s DFGN-101 enters clinical development through a streamlined FDA pathway
DifGen’s DFGN-101 can enter clinical testing after FDA IND clearance, advancing a single-injection approach for advanced breast cancer.
Pharma & Biotech